stomach pain from glp 1 GLP-1 Intolerance and Endoscopic Sleeve Options Combating the Unwelcome Side Effects
Description
45 Remarkably, the recent SELECT trial proved the cardiovascular efficacy of subcutaneous semaglutide in reducing the primary cardiovascular composite endpoint (death from cardiovascular causes, non-fatal MI or non-fatal stroke) in both overweight and obese patients with established atherosclerotic CVD
| Killion, EA., et al
Biol Psychiatry 2017;81:73747
doi: 10.1124/pr.116.013367
The New England Journal of Medicine
